Published on 21/11/2011
Around 9,000 cancer patients are being asked to take part in new gene tests, which could one day be used to create targeted cancer treatments.
Cancer Research UK’s multi-million pound Stratified Medicine Programme aims to establish a world-class NHS genetic testing service for cancer patients in the UK.
Medical staff in seven of Cancer Research UK's existing Experimental Cancer Medicine Centres (ECMCs) will be asking up to 9,000 patients to participate in the first phase of the Programme.
These 9,000 patients, suffering from six different types of cancer, will be asked to give consent for a small sample of their tumour to be sent to one of three leading NHS genetic testing labs. At the labs, DNA will be extracted and analysed for a range of molecular faults linked to cancer.
The results will be kept alongside a range of other clinical information, such as patients' drug regimes, to find the best treatments for specific faults. The study will not alter patient’s existing treatment.
Professor Malcolm Mason, lead researcher at the Cardiff ECMC, said: "This will play a key part in making targeted treatments available for cancer patients across the UK.
"We are extremely grateful to all these patients who, by contributing to this research, are allowing us to take great strides towards beating cancer."
Patients with private medical insurance often have access to new drugs and treatments not available on the NHS. This could include targeted cancer treatments. Compare health insurance policies online now guarantee you are eligible for cutting edge treatment in the future.
© ActiveQuote Ltd. 2011Categories: Medical